Hard Road for Medical Treatments
Only a tiny fraction of the compounds tested for different diseases ever make it to clinical trials. Now a report in Science suggests that the results of even encouraging clinical trials are later refuted with surprising frequency.
Scientists from the University of Ioannina School of Medicine in Greece analyzed published studies, from 1990 to 2004, of promising new drug candidates or medical devices. (A sampling is shown at below.) Of 32 interventions described in these papers, each of which had been cited more than 1,000 times, 13 were later shown not to work or to be less effective than originally thought.
Seven of the studies investigated new applications of well-known compounds; of these, six were later refuted. The report concludes that studies of new compounds and devices are a better use of research money.
“For common diseases, continuing to play with old agents and interventions is unlikely to give us much hope for finding some major effective intervention that we were not already aware of,” says John Ioannidis, senior author of the study.

Source: John Ioannidis
Keep Reading
Most Popular
Geoffrey Hinton tells us why he’s now scared of the tech he helped build
“I have suddenly switched my views on whether these things are going to be more intelligent than us.”
ChatGPT is going to change education, not destroy it
The narrative around cheating students doesn’t tell the whole story. Meet the teachers who think generative AI could actually make learning better.
Meet the people who use Notion to plan their whole lives
The workplace tool’s appeal extends far beyond organizing work projects. Many users find it’s just as useful for managing their free time.
Learning to code isn’t enough
Historically, learn-to-code efforts have provided opportunities for the few, but new efforts are aiming to be inclusive.
Stay connected
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.